hero image



Delays in timely diagnosis of multiple myeloma

Delays in diagnosis of patients with multiple myeloma impact both complications and outcomes1


Complex treatment decision-making in multiple myeloma

The complex myeloma treatment paradigm can impact optimal treatment decision-making2-5

Clinical Trial Results

Limited applicability and diversity of clinical trials

Multiple myeloma trials often do not reflect real-world populations, limiting application of results in clinical practice6


Inconsistent holistic management of multiple myeloma

Current care models may not effectively address the broader needs of patients consistently, including psychosocial support and shared decision-making7,8

Across the globe, unmet needs remain from a treatment, care pathway, and patient experience perspective.

To answer this, the Global MM Collaboration Council worked together to identify high-priority unmet needs forming the basis of the Call-to-Action.

Watch the video to find out more.

Dr. Paula Rodríguez Otero, Hematology and Hemotherapy Specialist at the University of Navarra in Spain and a member of the Collaboration Council, connected with Lori Parisi, Vice President of Global Medical Affairs at Johnson & Johnson to discuss the Call-to-Action.

This conversation focuses on timely diagnosis and proposed actions to improve outcomes for people living with multiple myeloma.

image video

Meet our experts

Johnson & Johnson has brought together experts from across geographies and disciplines to represent the perspectives of multiple audiences in multiple myeloma care.


The Call-to-Action

Download our summary highlighting the most critical unmet needs, as identified by the Collaboration Council, and actionable steps to advance multiple myeloma care for everyone across the globe.


Abbreviations & References

MM, multiple myeloma.

  1. Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100(10):635-40.
  2. Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation. 2016;51(4):479-91.
  3. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105(10):2358-67.
  4. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, et al. Second line treatment strategies in multiple myeloma: a referral-center experience. Blood. 2021;138(Supplement 1):819.
  5. Hernández-Rivas J, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1.
  6. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40.
  7. Quinn B, Ludwig H, Bailey A, Khela K, Marongiu A, Carlson KB, et al. Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. Pain Manag. 2022;12(1):59-74.
  8. Doubova SV, Terreros-Muñoz E, Delgado-Lòpez N, Montaño-Figueroa EH, Infante-Castañeda C, Pérez-Cuevas R. Experiences with health care and health-related quality of life of patients with hematologic malignancies in Mexico. BMC Health Serv Res. 2020;20(1):644.

This Call-to-Action outlines high-priority unmet needs and recommended areas of focus for the global multiple myeloma community, as identified by the Collaboration Council.